Trial Profile
Protocol B4Z-MC-LYDO(b) Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Acronyms LYDO
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
- 07 Jun 2012 Results presented at the 28th International Congress of Collegium Internationale Neuro Psychopharmacologicum.